Lonza to Buy U.S. Manufacturing Facility From Roche For $1.2 Billion
By Andrea Figueras
Lonza agreed to buy a manufacturing facility in the U.S. from Roche for around $1.2 billion in cash as it seeks to boost growth of its biologics division.
The deal, due to close in the second half subject to customary conditions, is expected to increase sales growth, the Swiss life-sciences company said Wednesday, raising its mid-term target for 2024-28.
Lonza now estimates a compound annual sales growth rate between 12% and 15% at constant currency, while it previously anticipated it in a range of 11% to 13%.
The rest of its guidance remains unchanged.
Lonza plans to invest around CHF500 million to upgrade the Genentech facility in Vacaville, Calif., one of the largest biologics manufacturing sites in the world by volume.
Roche's products currently manufactured at the site will be supplied by Lonza, with committed volumes over the medium term, phasing out over time, Lonza said.
As part of the agreement, Lonza will offer employment to some 750 Genentech workers at the U.S. facility.
The deal is expected to boost the company's large-scale biologics manufacturing capacity, helping it meet demand for commercial mammalian contract manufacturing from customers with existing commercial products, and molecules currently on the path to commercialization, it said.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
March 20, 2024 02:59 ET (06:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software